Engflag

Insugen N

Quick links to important sections

Insugen N

Insugen N_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Insugen N

Insugen N is a prescription-only anti-diabetic agent manufactured by Biocon Ltd., primarily serving markets in India and other emerging economies, which distinguishes its regional focus from global counterparts.

Property Description
Active ingredient Insulin human (Isophane Insulin)
Form Suspension for injection (Vial, Cartridge, or Penfill)
Pharmacological class Intermediate-acting Insulin preparation
Common use Basal coverage for high blood glucose levels (Hyperglycemia)
Origin Bio-synthetic (Recombinant DNA technology)

Insugen N: A Classification as Intermediate-Acting Insulin

Insugen N is formally classified as an Insulin preparation, specifically belonging to the intermediate-acting category. The active component, Insulin human, is structurally identical to the insulin naturally produced by the human pancreas. The drug entity is formally known as Isophane Insulin Human Suspension. Intermediate-acting insulins are designed to provide foundational, or basal, glucose control for individuals with diabetes mellitus. This sustained action plays a role in managing blood sugar levels over a substantial portion of the day and overnight.

Composition, Origin, and Dosage Form

The active ingredient in Insugen N is Insulin human (Isophane Insulin), a bio-synthetic compound produced using recombinant DNA technology. It is supplied as a sterile, cloudy suspension for injection, distinguishing it visually from clear, rapid-acting solutions, and is administered via the subcutaneous administration route. Its formulation includes protamine and zinc, which are essential for its delayed action profile. This modification slows the absorption rate, which is the mechanism that provides the characteristic intermediate duration of action. While Insugen N is one established brand, other intermediate-acting Isophane Insulin brands with the same formulation include Humulin N and Novolin N, which provide similar therapeutic profiles across different manufacturers.

Regulatory References

  1. recognized by the European Medicines Agency (EMA)
  2. U.S. National Library of Medicine (NIH)

What side effects are possible with Insugen N?

Possible Side Effects and Safety Information

The safety profile for Insugen N (Isophane Insulin human) is strictly governed by regulatory classifications, focusing primarily on the metabolic consequences of insulin therapy. The medication is formally contraindicated during episodes of existing low blood sugar (hypoglycemia) or in individuals with known hypersensitivity to the drug's components.

The most frequent adverse event is documented as Hypoglycemia, which is classified as Very Common (ge 1/10) in official regulatory documents. This is an expected consequence of the glucose-lowering action of insulin.

Less frequent adverse reactions are categorized by the body system affected, as follows:

Classification Affected System (SOC) Adverse Reactions
Common Skin & Subcutaneous Tissue Local Injection Site Reactions, Weight Gain, Oedema
Uncommon Skin & Subcutaneous Tissue Lipodystrophy (Lipoatrophy, Lipohypertrophy)

Serious adverse reactions, though rare, are documented in official labeling and include Severe Hypoglycemia (potentially leading to seizures or unconsciousness), Systemic Hypersensitivity (Anaphylaxis), and severe Hypokalemia (low potassium levels).

Time-Related Safety Patterns include reports of transient visual disturbances and mild peripheral neuropathy that may occur during the initial phase of treatment when blood sugar control improves rapidly. Furthermore, the risk of Lipohypertrophy is associated with long-term use if injection sites are not adequately rotated.

Population-Specific Considerations noted in regulatory documents specify that individuals with Renal or Hepatic Impairment may have altered insulin requirements, which increases the risk of hypoglycemia. Official safety constraints also mandate that multi-dose insulin pens or syringes must never be shared between patients.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for an overdose of Insugen N, an intermediate-acting Insulin human, is strictly defined by the consequences of absolute or relative insulin excess, resulting in Hypoglycaemia (low blood glucose). This condition may manifest across a spectrum of symptoms, ranging from mild to life-threatening.

Documented manifestations of overdose include mild symptoms such as sweating, tremor, anxiety, and confusion. Severe manifestations, which constitute a medical emergency, include seizures and loss of consciousness (coma).

Required Emergency Actions

The labeling mandates that patients seek immediate medical attention for all severe symptoms. Management depends on severity: mild hypoglycemia is managed with oral glucose or sugar products. Severe, life-threatening episodes require parenteral intervention, such as the administration of Glucagon or Intravenous (IV) glucose solution. Following severe events, close hospital observation and intensified blood glucose monitoring are required to prevent recurrence.

Population-Specific Overdose Considerations

The official labeling notes that patients with renal impairment, hepatic impairment, or older adults may be at an increased risk of severe hypoglycemia due to altered insulin clearance, a factor that requires heightened consideration when assessing the severity of a suspected overdose. The life-threatening outcomes of severe hypoglycemia include coma and death, underscoring the necessity for prompt intervention.

Therapeutic Uses of Insugen N

Insugen N provides therapeutic support for individuals with Diabetes Mellitus by addressing the core problem of chronic hyperglycemia. This intermediate-acting insulin is used to stabilize blood sugar levels throughout the day and night, providing supportive basal glucose control.

Key Therapeutic Focus

This medication is primarily indicated for treating Type 1 Diabetes, Type 2 Diabetes (when oral treatments are insufficient), and Gestational Diabetes that cannot be managed by diet alone. It is commonly used to help with the disruptive symptom cluster caused by persistently high blood sugar, including excessive thirst (polydipsia), frequent urination (polyuria), and chronic fatigue.

By supporting glucose stability, Insugen N contributes to improved daily comfort. This intermediate-acting profile is used for maintaining stable blood sugar during fasting states and overnight, assisting with the body's continuous need for basal insulin.

“This foundational therapy may play a role in managing the risk of long-term complications associated with chronic high blood sugar.”

Quick Fact: Relief for Persistent Fatigue

Insugen N contributes to easing the systemic strain of chronic hyperglycemia, supporting the patient during difficult episodes and assisting with maintaining functional stability by managing symptoms related to systemic imbalance.

Eligibility and Restrictions for Use

Insugen N (Isophane Insulin Human) has established rules defining who can and cannot use the medicine, based on official regulatory labeling.

Absolute Contraindications

The medicine must not be used during episodes of hypoglycemia (low blood sugar). It is also strictly contraindicated for patients with a known history of hypersensitivity reactions (allergy) to Isophane Insulin Human or any excipients in the formulation.

General Population Eligibility

Insugen N is formally indicated for use in both adult patients and pediatric patients diagnosed with diabetes mellitus.

Conditional Use and Restrictions

Specific populations require conditional use. Patients with renal impairment or hepatic impairment are at a heightened risk of hypoglycemia and require close clinical supervision. Additionally, when Insugen N is used concurrently with Thiazolidinediones (TZDs), observation for signs of heart failure is required, as the combination may cause or worsen the condition.

Use in Special Groups

Human insulin is the accepted treatment for managing diabetes during pregnancy. Use during lactation is generally allowed, as the insulin is not expected to cause adverse effects in the nursing infant. Older adults are permitted to use the medicine but may face an increased risk of hypoglycemia due to co-morbidities.

What should I know about interactions with other medicines?

Interactions with other Medicines and Products

The official interaction profile for Insugen N (Isophane Insulin human) is defined by pharmacodynamic effects that alter the body’s glucose balance, rather than by pharmacokinetic mechanisms. No interactions involving CYP450 enzymes or drug transporters are explicitly documented in regulatory prescribing information. The primary concern is the modification of the insulin requirement by co-administered substances.

Co-administration with several medicinal product categories may increase the blood glucose-lowering effect, raising the risk of hypoglycemia. These categories include Oral Antidiabetic Agents (such as MAOIs and high-dose salicylates). Conversely, agents like Corticosteroids, Thyroid Hormones, and Sympathomimetic Agents may decrease the blood glucose-lowering effect, leading to an increased insulin requirement.

A non-glycemic risk is documented for co-administration with Thiazolidinediones (e.g., Pioglitazone), which is officially associated with fluid retention that may lead to or exacerbate heart failure. Furthermore, drugs such as Beta-Blockers may blunt or mask the signs of hypoglycemia. The regulatory label states that alcohol may have a variable effect, intensifying or reducing the insulin's action. A mandatory constraint is that Insugen N must not be mixed with insulin preparations from different manufacturers.

Mechanism of Action

Insugen N is an intermediate-acting form of human insulin that functions as a hormone receptor agonist. Its primary mechanism involves binding to the transmembrane Insulin Receptor (IR), a protein complex found on the surface of most body cells, particularly muscle, fat, and liver cells. This binding event initiates the activation of the receptor's intrinsic tyrosine kinase domain, which triggers a complex intracellular signal transduction cascade (primarily the IRS/PI3K/Akt pathway).

This cascade results in two main physiological modulations. First, it promotes the translocation and insertion of GLUT4 glucose transporters into the plasma membrane of muscle and adipose tissue, which facilitates the transport of glucose from the plasma into the intracellular space. Second, in the liver, the activated pathways exert a potent anti-catabolic effect by suppressing key enzyme systems involved in gluconeogenesis and glycogenolysis. By concurrently enhancing peripheral glucose uptake and inhibiting endogenous hepatic glucose output, the drug contributes to the overall effect of reduced plasma glucose concentration in the circulation.

Dosage and Administration Information

Administration Overview

Insugen N is an intermediate-acting insulin typically administered via subcutaneous injection. Proper administration technique is necessary to ensure the medication is absorbed consistently. Common injection sites include the abdomen, thighs, buttocks, or upper arms.

Preparation

Before use, the insulin suspension must be resuspensioned. This is generally achieved by gently rolling the vial or pen between the palms or inverting it until the liquid appears uniformly cloudy or milky. It is important to avoid vigorous shaking, as this can create air bubbles and affect the accuracy of the dose.

Injection Technique

The injection is performed into the fatty tissue layer just beneath the skin. The specific site should be cleaned prior to injection. To prevent the development of skin changes such as lumps or pits (lipodystrophy), it is important to rotate the injection site within the chosen body area so that the same spot is not used too frequently.

Storage and Handling

Insugen N requires specific temperature controls to maintain its stability. Vials or pens currently in use are often kept at room temperature for a limited period, while unopened containers are typically stored in a refrigerator. The medication should be protected from direct heat and light, and it should never be frozen.

Recent Clinical Evidence

Research evidence / Overview of studies for Insugen N

The research base for Insugen N (Isophane Insulin Human) was studied for many decades and is a conventional type of intermediate-acting insulin that was studied for many decades. The following sections describe what the studies have examined and what data show patterns related to, according to official and peer-reviewed scientific sources.

Evidence for Use in Type 1 and Type 2 Diabetes Mellitus

The majority of research was evaluated in adult and pediatric populations with Type 1 Diabetes and in insulin-naive adults with Type 2 Diabetes. These conditions characterized by fluctuating or episodic manifestations were the primary focus of Randomized Controlled Trials (RCTs) and Systematic Reviews.

The main outcomes related to systemic or functional imbalance that researchers monitored were blood sugar control markers, primarily Glycated Hemoglobin (HbA1c) and Fasting Plasma Glucose (FPG). Studies also explored the frequency of hypoglycemia events (low blood sugar), as well as changes measured during the study period related to body weight. Findings describe patterns observed in the studies regarding HbA1c changes over time. Research also highlights changes measured during the study period concerning the risk of both overall and nocturnal hypoglycemia.

Despite the volume of research, long-term outcomes are not fully established by the majority of comparative trials. Many studies featured follow-up durations that were limited to 6 months or less, meaning that the research provides limited information for long-term outcomes such as major diabetes-related complications. Similarly, data for certain groups remain insufficient regarding patient-reported outcomes describing perceived discomfort and health-related quality of life.

Evidence in Unique Clinical Contexts

Research for Use in Gestational Diabetes Mellitus (GDM)

The use of this insulin was evaluated in pregnant women with Gestational Diabetes through Systematic Reviews and dedicated Randomized Clinical Trials. Researchers examined outcomes related to physical discomfort and health for both the mother and the newborn. Specifically, studies monitored maternal clinical events such as the development of pre-eclampsia and fetal outcomes like birth weight and the risk of neonatal hypoglycemia.

Findings describe patterns observed in the studies regarding findings related to maternal blood glucose targets throughout the pregnancy. Research describes the frequency of maternal complications, including the incidence of pre-eclampsia. The volume of dedicated research is limited in this population compared to non-pregnancy diabetes. The evidence quality varies across studies and has been noted for potential imprecision.

Studies Regarding Transition from Acute Therapy

This insulin was studied for its role in the transition phase following acute hyperglycemic crises, such as Diabetic Ketoacidosis (DKA). Research in this area primarily consists of small-scale Randomized Controlled Trials focusing on episodes where symptoms become more noticeable and require hospitalization. Studies explored outcomes describing episodic or acute changes, including the time required for acidosis resolution, the overall duration of the hospital stay, and the frequency of hypoglycemia events during the transition.

Long-Term Studies and Durability of Response

Research has examined various follow-up durations to understand the observation periods for this insulin. While many trials are short-term, some studies monitored patients for intermediate periods (up to one year) and regulatory assessments have referenced data from long-term cohorts observing responses over defined time intervals stretching up to five years.

Evidence Gaps and Areas of Uncertainty

Comparative evidence is lacking or evidence quality varies across studies for some key outcomes, notably the absolute incidence of severe hypoglycemia in comparison studies. This means that while the evidence contributes to understanding symptom patterns, subgroup findings are uncertain in some areas.

Key Studies & References Long-term follow-up of children and adolescents with type 1 diabetes on NPH insulin compared with insulin glargine: a large multicenter DPV registry study

Frequently Asked Questions (FAQ)

Common questions about Insugen N (FAQ)

Q: What is the main difference between Insugen N and Insugen R?

Insugen N is classified as an intermediate-acting insulin (NPH insulin), providing a sustained foundation, or basal, level of glucose control. Insugen R (Regular Human Insulin) is a short-acting insulin, typically administered to address mealtime blood sugar spikes. A physical difference is that Insugen N is a cloudy suspension, whereas Insugen R is a clear solution.

Q: How quickly does Insugen N start working after injection?

Official product information on the pharmacodynamics of NPH insulin indicates that the onset of action typically begins 1 to 3 hours after it is injected under the skin (subcutaneously).

Q: Can I drink alcohol while taking Insugen N?

Official product information states that alcohol may have a variable effect, intensifying or reducing the insulin's action, and may increase the risk of hypoglycemia (low blood sugar).

Q: What are some common medications that might interact with Insugen N?

Many drug categories can alter insulin requirements. For instance, medications that may decrease the blood glucose-lowering effect (requiring more insulin) include corticosteroids and thyroid hormones. Conversely, some oral antidiabetic agents may increase the blood sugar-lowering effect.

Q: Does Insugen N need to be refrigerated all the time?

Unopened vials or pens must be kept refrigerated, generally between 2 C and 8 C. However, once a vial or pen is in use (opened), it should be stored at room temperature (not exceeding 25 C to 30 C) for the recommended in-use period, as specified in the product labeling.

Q: How long is an open vial of Insugen N good for?

An unopened vial is viable until its expiration date if properly refrigerated. Once a vial of Insugen N is opened and in use, it is typically stable for up to 28 days when stored at room temperature, away from heat and light. The patient should always refer to the specific expiration date and in-use period noted on their product packaging.

Q: Why do some people inject Insugen N twice a day?

Insugen N is often administered once or twice daily, as determined by a healthcare provider. The twice-daily schedule may be selected because the total duration of the intermediate action is intended to help maintain glucose control throughout the day and overnight.

Q: What is the connection between Insugen N and managing nighttime blood sugar?

Insugen N is an intermediate-acting basal insulin. Due to its sustained duration of action, it is used as a foundation, or basal insulin, and is often timed to help prevent blood sugar from rising excessively overnight while the person is fasting or sleeping.

Q: Is it normal for my injection site to look red or slightly swollen after using Insugen N?

Local injection site reactions are classified as a common adverse event. This can include temporary redness or slight swelling at the injection site. This type of reaction should be discussed with a healthcare provider.

Q: What is the typical peak action time for Insugen N?

According to the pharmacodynamic profile of NPH insulin, the blood sugar-lowering effect of Insugen N typically peaks between 4 and 8 hours after it is injected under the skin.

Q: Can Insugen N be mixed with short-acting insulin?

Regulatory information for Insugen N strictly mandates that it must not be mixed with insulin preparations from different manufacturers. The appropriate use and mixing of any insulins should always be determined by a healthcare provider.

Q: Does Insugen N affect my blood pressure?

There is no direct listing of blood pressure changes as a primary side effect of Insugen N itself. However, co-administration with certain drugs (like thiazolidinediones) is noted in regulatory documents to cause fluid retention that may lead to or worsen heart failure.

Q: Can I travel internationally with Insugen N and keep it stable?

To maintain stability during travel, the patient must adhere to the specific storage guidelines. Unopened insulin requires refrigerated storage (2 C to 8 C), and all insulin must be protected from freezing, direct heat, and direct light to maintain its potency.

Q: Does Insugen N have any effects on my kidneys over time?

Insugen N is not documented to cause kidney damage. However, official safety constraints note that individuals with pre-existing renal impairment (kidney issues) may experience an altered insulin requirement, which may increase their risk of low blood sugar (hypoglycemia).

Q: What are the signs that my Insugen N might be expired or ineffective?

Insugen N that has been frozen or improperly stored should be safely discarded, as recommended by product labeling. Before injection, the suspension must appear uniformly white and cloudy after being gently mixed. Do not use the medicine if it is discolored or contains any solid particles.

Q: Can extreme heat or cold affect the potency of Insugen N?

Yes, temperature extremes can severely compromise the effectiveness of the insulin. It is critical that insulin is never frozen and that it is stored away from direct heat and light to maintain its potency.

Q: Are there specific storage instructions for Insugen N pens?

As with vials, unopened pens/cartridges must be stored in the refrigerator. Once in use, the pens/cartridges should be stored at room temperature for a duration that may be shorter than vials, commonly 14 to 28 days, depending on the specific device.

Q: Does Insugen N interact with common over-the-counter pain relievers?

Official interaction profiles indicate that high-dose salicylates (a component found in some pain relievers, such as aspirin) may increase the blood sugar-lowering effect of insulin.

Q: Can stress or illness change how effective Insugen N is?

Yes, regulatory precautions state that a person’s insulin requirements can change significantly when they are under stress or experiencing an illness. Major changes in diet or exercise can also affect how much insulin is needed.

Q: What is the risk of hypoglycemia (low blood sugar) with Insugen N?

Hypoglycemia (low blood sugar) is the most frequently documented adverse event associated with Insugen N and is classified as Very Common (ge 1/10) in official regulatory documents. This is an expected consequence of using insulin to lower blood sugar.

Q: Does the time of day I inject Insugen N matter?

Yes. While the dosage and timing are tailored by a physician, Insugen N is administered once or twice daily. The injection time is carefully chosen, sometimes at bedtime, to ensure effective management of blood sugar, particularly to control fasting blood glucose levels.

Q: What should be included in a basic emergency kit for someone on Insugen N?

Given the Very Common risk of hypoglycemia (low blood sugar), the kit should include a source of fast-acting glucose (like glucose tablets or juice). Official guidance suggests that the patient should discuss the need for an emergency glucagon kit with their healthcare provider for managing severe low blood sugar events.

Q: Can certain antidepressants or beta-blockers interact with Insugen N?

Official documents explicitly state that Beta-Blockers may mask or blunt the signs of hypoglycemia (low blood sugar), making it harder to recognize. Additionally, co-administration with any agent that affects blood glucose levels, including certain antidepressants, requires close monitoring.

Q: What's the difference in how Insugen N and long-acting insulins look?

Insugen N (NPH insulin) is formulated as a cloudy suspension that must be gently mixed before injection. In contrast, many of the newer long-acting insulin analogs are formulated as clear solutions.

How should Insugen N be stored and disposed of?

Insugen N (Isophane Insulin Human) requires specific storage conditions to maintain its effectiveness. Unopened vials, cartridges, or pens must be stored in a refrigerator, typically between 2 C and 8 C. It is critical not to freeze insulin, and any insulin that has been frozen must be discarded.

Once in use (opened), Insugen N should be stored at room temperature, generally not exceeding 25 C to 30 C (or 86 F), and away from direct heat and light. The in-use period varies by product type but is commonly up to 28 days for vials and between 14 to 28 days for pens/cartridges. Always check the expiration date on the package and discard any insulin past this date or after the specified in-use period.

Used needles, syringes, and pen needles must be safely disposed of immediately after use in a puncture-resistant sharps container. Follow local guidelines for the proper disposal of both the sharps container and expired or unused medication. Never throw sharps loosely into household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Insugen N found in:

A-Z Index: